探索GHK-Cu对实验性结肠炎模型的益处及其潜在机制

Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.

作者信息Shuzhen Mao, Jiahui Huang, Junyan Li, Fang Sun, Qilian Zhang, Qing Cheng, Wei Zeng, Dongya Lei, Shiyan Wang, Jing Yao
PMID40672369
发布时间2025-07-16
DOI10.3389/fphar.2025.1551843

实验完整度

高

包含DSS小鼠模型、体外共培养、网络药理学、分子对接、基因沉默等多层级验证,明确功能与机制验证。

主要模型

BALB/c小鼠DSS诱导的溃疡性结肠炎模型 小鼠腹腔巨噬细胞(MPMs) 小鼠结肠上皮细胞(MCECs) MPMs与MCECs共培养模型

重点核对

DSS诱导浓度(3%)及处理时间(12天) GHK-Cu给药剂量(20 mg/kg)及途径(灌胃) 5-ASA阳性对照剂量(40 mg/kg) LPS刺激MPMs浓度(1 μg/mL) siSTAT3转染实验验证STAT3作用

摘要

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by mucosal damage and impaired epithelial barrier function. While glycyl-l-histidyl-l-lysine-copper (GHK-Cu) exhibits known anti-inflammatory properties, its therapeutic mechanisms in UC remain undefined. This study was designed to systematically evaluate the therapeutic potential of GHK-Cu in a dextran sulfate sodium (DSS)-induced murine model of UC, with particular emphasis on elucidating its regulatory effects on the NAD-dependent deacetylase sirtuin-1 (SIRT1)/signal transducer and activator of transcription 3 (STAT3) signaling pathway.Methods: UC was induced in BALB/c mice with 3% DSS for 14 days. The protein expression levels of tight junction associated protein-1 (ZO-1), Occludin, inflammatory factors interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF)-α, SIRT1, STAT3, p-STAT3, and retinoic acid receptor-related orphan receptor gamma t (RORγt) were detected by Western blot. Histopathological changes were evaluated by Hematoxylin and Eosin (H&E) and Alcian blue-periodic acid-Schiff (AB-PAS). Network pharmacology and molecular docking were used to predict the core targets of GHK Cu in the treatment of UC. An in vitro UC model was also established in mouse peritoneal macrophages (MPMs) using lipopolysaccharide (LPS), and a co culture model was constructed using mouse colonic epithelial cells (MCECs) and MPMs to examine the role of GHK Cu in promoting mucosal healing. STAT3 was silenced by gene transfection technology to verify the core role of STAT3 in GHK Cu treatment of UC.Results: GHK-Cu alleviated weight loss, improved the disease activity index (DAI), reduced colonic edema and shortening, attenuated inflammatory damage, increased goblet cell numbers, suppressed inflammatory cytokines such as TNF-α, IL-6, and IL-1β, and promoted mucosal repair. Additionally, a co-culture system of MCECs and MPMs revealed that GHK-Cu facilitated MCECs healing, impaired by DSS, by upregulating ZO-1 and Occludin expression. Subsequently, network pharmacology and molecular docking identified SIRT1 as a potential target of GHK-Cu. Results showed that GHK-Cu upregulated SIRT1 protein expression and suppressed the expression of phosphorylated p-STAT3 in colon tissue and MCECs of the co-culture model. Our findings revealed that after transfection with STAT3-targeting siRNA (siSTAT3), the stimulant effect of GHK-Cu on the healing of MCECs and the effect on the protein expression of ZO-1 and Occludin is canceled. Nevertheless, after transfection with siSTAT3, it could inhibit the expression of inflammatory factors in conjunction with GHK-Cu. Furthermore, we found that GHK-Cu could inhibit RORγt expression in the colon tissue of UC mice.Discussion: This study found that GHK-Cu demonstrated significant therapeutic effects in DSS-induced UC in mice. GHK-Cu may promote mucosal healing and enhance tight junction protein expression by regulating the SIRT1/STAT3 pathway. In addition to suppressing p-STAT3 expression, GHK-Cu may utilize additional pathways to inhibit inflammatory factors. Furthermore, GHK-Cu may reduce the number of Th17 cells. In summary, GHK-Cu may treat UC by acting on the SIRT1/STAT3 pathway.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
GHK-Cu是否对DSS诱导的溃疡性结肠炎具有治疗作用,其机制是否涉及SIRT1/STAT3通路。
核心机制
GHK-Cu通过上调SIRT1表达,抑制STAT3磷酸化,从而调节SIRT1/STAT3通路,促进黏膜愈合并抑制炎症。
主要证据
DSS小鼠模型中GHK-Cu减轻症状并调节SIRT1/STAT3;体外共培养中GHK-Cu促进MCECs迁移并上调ZO-1/occludin;siSTAT3敲低取消促愈合作用。
研究意义
为GHK-Cu治疗溃疡性结肠炎提供潜在的新策略,可能作为安全有效的治疗药物。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

建立DSS诱导的UC小鼠模型

评估GHK-Cu对实验性结肠炎的整体治疗效果

使用3% DSS诱导BALB/c小鼠结肠炎,GHK-Cu灌胃处理,评估体重、DAI、结肠长度、CMDI和组织病理学变化。

2

检测炎症因子和紧密连接蛋白表达

验证GHK-Cu对炎症和黏膜屏障的影响

Western blot检测结肠组织中IL-1β、IL-6、TNF-α、ZO-1、Occludin的表达。

3

体外共培养模型模拟黏膜愈合

研究GHK-Cu对结肠上皮细胞迁移和紧密连接蛋白的作用

MCECs与MPMs共培养,DSS处理MPMs,GHK-Cu处理,进行划痕实验和Western blot检测ZO-1/Occludin。

4

网络药理学和分子对接预测靶点

预测GHK-Cu治疗UC的核心靶点

通过网络药理学筛选GHK-Cu和UC的共同靶点,分子对接验证GHK-Cu与SIRT1的结合。

5

验证SIRT1/STAT3通路调节

验证GHK-Cu对SIRT1和STAT3信号通路的影响

Western blot检测结肠组织和共培养MCECs中SIRT1、p-STAT3、STAT3的表达。

6

siSTAT3基因沉默验证STAT3作用

确认STAT3在GHK-Cu促进黏膜愈合和抑制炎症中的核心作用

在共培养MCECs中转染siSTAT3,观察划痕愈合和ZO-1/Occludin表达;在LPS刺激的MPMs中转染siSTAT3,检测炎症因子。

7

检测RORγt表达

探究GHK-Cu对Th17细胞分化的影响

Western blot检测结肠组织中RORγt的表达。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

动物模型构建与处理
蛋白表达检测
细胞功能检测
共培养模型
网络药理学分析
分子对接
基因沉默

产品清单

实验环节名称品牌货号
葡聚糖硫酸钠MP Biomedicals160110
5-氨基水杨酸AladdinA129982
粪便隐血定性检测试剂盒Shanghai YuanyeR24187
脂多糖SigmaL6529
MTT细胞增殖和细胞毒性检测试剂盒BeyotimeC0009S
红细胞裂解液SolarbioR1010
二甲基亚砜SolarbioD8371
Occludin单克隆抗体Proteintech66378
STAT3多克隆抗体Proteintech10253-2-AP
ZO-1抗体AffinityAF5145
β-肌动蛋白抗体AffinityAF7018
山羊抗小鼠IgG(H+L)HRPAffinityS0002
山羊抗兔IgG(H+L)HRPAffinityS0001
兔抗TNF-α多克隆抗体Bioss2081R
兔抗IL-6多克隆抗体Bioss0782R
抗IL-1β兔多克隆抗体ServicebioGB11113
抗SIRT1抗体Abcam189494
抗RORγ抗体Abcam207082
磷酸化Stat3(Tyr705)兔单克隆抗体Cell Signaling Technology91455
Transwell渗透性支持物Corning3412
Lipofectamine 2000Thermo Fisher11668500
STAT3靶向siRNAGeneChem1348C5

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
动物模型
DSS浓度(3%)、处理时间(12天)、动物品系(BALB/c)、性别(雄性)、年龄(6-8周)、体重(18-22g)、饲养条件(温度、湿度、光照)、动物分组(n=8)
阅读提示:材料与方法 2.2和2.3
给药方案
GHK-Cu剂量(20 mg/kg)、给药途径(灌胃)、给药时间(14天)、5-ASA剂量(40 mg/kg)、对照组处理(生理盐水灌胃)
阅读提示:材料与方法 2.3
体外细胞实验
MCECs培养条件(高糖DMEM、10%FBS、1%P/S)、MPMs获取(3%巯基乙酸盐腹腔注射,72小时)、LPS浓度(1 μg/mL)、GHK-Cu处理浓度(62.5 μM)和时间(18小时)、共培养条件(0.4 μm Transwell)
阅读提示:材料与方法 2.9、2.10、2.11
基因沉默
siSTAT3转染方法(Lipofectamine 2000)、转染效率验证、处理时间
阅读提示:材料与方法 2.12
蛋白检测
一抗来源及稀释度、二抗来源、蛋白提取方法、内参选择(β-actin)
阅读提示:材料与方法 2.13